ITCI Intra-Cellular Therapies, Inc.: institutional ownership and insider trading
5 funds reported holding $45.1M of Intra-Cellular Therapies, Inc. in their latest 13F filings; in Q2 2026 funds net bought $0, with 0 new positions and 0 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market; over its last four quarters it reported revenue of $681M and net income of −$74.7M.
ITCI revenue and earnings
- Quarter ended Dec 31, 2024: revenue $199M, net income −$16.9M, EPS -0.16
- Quarter ended Sep 30, 2024: revenue $175M, net income −$26.3M, EPS -0.25
- Quarter ended Jun 30, 2024: revenue $161M, net income −$16.2M, EPS -0.16
- Quarter ended Mar 31, 2024: revenue $145M, net income −$15.2M, EPS -0.16
Largest institutional holders of ITCI
- Nuveen Asset Management, LLC — $43.4M
- Orion Portfolio Solutions, LLC — $1.65M
- Lindbrook Capital, LLC — $48.4K
- HUNTINGTON NATIONAL BANK — $2.54K
- Cassady Schiller Wealth Management, LLC — $1.09K
Recent ITCI insider trades
- Dec 5, 2024: Mates Sharon sold 102,697 shares ($8.72M)
- Nov 13, 2024: Halstead Michael sold 41,583 shares ($3.69M)
Members of Congress trading ITCI
- Apr 3, 2025: Josh Gottheimer sold $1.00K–$15.0K
- Apr 3, 2025: Gilbert Ray Cisneros, Jr. sold $1.00K–$15.0K
- Mar 24, 2025: Gilbert Ray Cisneros, Jr. sold part of $1.00K–$15.0K
- Mar 17, 2025: Josh Gottheimer sold part of $1.00K–$15.0K
- Jan 24, 2025: Josh Gottheimer sold part of $1.00K–$15.0K
- Jun 21, 2024: Josh Gottheimer sold part of $1.00K–$15.0K